Literature DB >> 12356647

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Joseph S Alpert, David P Faxon, Valentin Fuster, Gabriel Gregoratos, Loren F Hiratzka, Alice K Jacobs, Sidney C Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356647     DOI: 10.1161/01.cir.0000037106.76139.53

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  179 in total

1.  Usefulness of electrocardiographic parameters as compared with computed tomography measures of left atrial volume enlargement: from the ROMICAT trial.

Authors:  Quynh A Truong; Elizabeth M Charipar; Leon M Ptaszek; Carolyn Taylor; Joao D Fontes; Matthias Kriegel; Thomas Irlbeck; Amir A Mahabadi; Ron Blankstein; Udo Hoffmann
Journal:  J Electrocardiol       Date:  2010-05-27       Impact factor: 1.438

2.  Same-day transfer of patients with unstable angina and non-ST segment elevation myocardial infarction back to their referring hospital after angioplasty.

Authors:  Doan Hoa Do; Karl Dalery; André Gervais; Richard Harvey; Serge Lepage; Andrée Maltais; Michel Nguyen
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

3.  Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial.

Authors:  P A Poole-Wilson; S J Pocock; K A A Fox; R A Henderson; D J Wheatley; D A Chamberlain; T R D Shaw; T C Clayton
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

4.  Revascularisation for acute coronary syndromes: PCI or CABG?

Authors:  J Gunn; D P Taggart
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 5.  In-hospital initiation of statin therapy in patients with acute coronary events.

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

6.  Antithrombotic therapy and the invasive cardiac catheterization management strategy: the intracoronary stenting with antithrombotic regimen cooling-off trial.

Authors:  Robert A Harrington
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

Review 7.  Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease.

Authors:  Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

8.  Sex differences in the treatment and outcome of patients with acute coronary syndrome after percutaneous coronary intervention: a population-based study.

Authors:  Chen-Fang Lin; Li-Jiuan Shen; Fei-Yuan Hsiao; Churn-Shiouh Gau; Fe-Lin Lin Wu
Journal:  J Womens Health (Larchmt)       Date:  2013-11-28       Impact factor: 2.681

9.  Presence and extent of coronary artery disease by cardiac computed tomography and risk for acute coronary syndrome in cocaine users among patients with chest pain.

Authors:  Fabian Bamberg; Christopher L Schlett; Quynh A Truong; Ian S Rogers; Wolfgang Koenig; John T Nagurney; Sujith Seneviratne; Sam J Lehman; Ricardo C Cury; Suhny Abbara; Javed Butler; Hang Lee; Thomas J Brady; Udo Hoffmann
Journal:  Am J Cardiol       Date:  2008-12-26       Impact factor: 2.778

Review 10.  Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.

Authors:  Nick Bosanquet; Bengt Jönsson; Keith A A Fox
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.